A below-the-signal beneficiary of the fiber revolution.
Mar 1, 2026
Apr 11, 2026
•
2 min read
Plus, a precision oncology biotech with room to run, a CNS drug challenger with nearly $4B in projected peak sales, and more...
Apr 4, 2026
Plus, a top-1% analyst's highest-conviction AI infrastructure bet and the post-IPO software name Goldman says the market is missing out on.
Apr 1, 2026
The market may be missing a protein upgrade that favors eggs.
